Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

Investors are expected to be cautious with AUROPHARMA, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.848000
forwardPE 15.225432
debtToEquity 22.248000
earningsGrowth 0.044000
revenueGrowth 0.063000
grossMargins 0.576220
operatingMargins 0.150730
trailingEps 58.970000
forwardEps 74.868160

AUROPHARMA's current ratio 1.848, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, AUROPHARMA can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
AUROPHARMA's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Aurobindo Pharma Limited's low Debt-to-Equity ratio indicates the company is not over-leveraged. By limiting its dependence on debt, Aurobindo Pharma Limited reduces its financial risk and demonstrates a strong capital structure, making it a more stable investment option for those wary of excessive borrowing.
AUROPHARMA's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that AUROPHARMA is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

The price of Aurobindo Pharma Limited has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


A recent buy bias from analysts toward AUROPHARMA may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that AUROPHARMA might be an appealing option for those looking to grow their wealth through stock market investments.